<DOC>
	<DOCNO>NCT00769548</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high energy x-rays damage tumor cell . Hormone therapy combine radiation therapy may effective treatment prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness four different combination radiation hormone therapy treat patient prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy Hormone Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Examine whether total androgen suppression ( TAS ) flutamide/goserelin whole-pelvic irradiation follow cone-down boost prostate improve progression-free survival 5 year least 10 % compare TAS prostate-only irradiation patient adenocarcinoma prostate significant risk nodal involvement . II . Examine whether induction concurrent ( neoadjuvant ) TAS radiotherapy improve progression-free survival 5 year least 10 % compare adjuvant TAS radiotherapy . III . Compare treatments regard local control , time distant failure , overall survival . OUTLINE : Randomized study . Arm I : Neoadjuvant Antiandrogen Therapy Radiotherapy . Flutamide , FLUT , NSC-147834 ; Goserelin , Zoladex , ZDX , NSC-606864 ; irradiation whole pelvis follow boost prostate use photon least 6 MV . Arm II : Neoadjuvant Antiandrogen Therapy Radiotherapy ; FLUT ; ZDX ; irradiation prostate use equipment Arm I . Arm III : Radiotherapy follow Adjuvant Antiandrogen Therapy . Irradiation Arm I ; follow FLUT ; ZDX . Arm IV : Radiotherapy follow Adjuvant Antiandrogen Therapy . Irradiation Arm II ; follow FLUT ; ZDX . PROJECTED ACCRUAL : 1,200 patient accrue 2.5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Any stage estimate risk node involvement least 15 % ( therefore significant risk local and/or systemic failure ) base pretreatment PSA Gleason score ( GS ) , e.g . : GS 7 PSA great 7.5 ng/mL GS 6 PSA great 22.5 ng/mL GS 5 PSA great 37.5 ng/mL PSA great 4 less 100 ng/mL Highest pretreatment value determine monoclonal assay normal range 04 ng/mL PSA measure polyclonal assay ( e.g. , Yang ) normal range 02.5 ng/mL may need divide conversion factor approximately 1.5 GS determination require prior entry No distant metastases No biopsy proven lymph node involvement Ineligible protocol RTOG9408 ( clinical stage T2cT4 GS 6 higher eligible study ) PATIENT CHARACTERISTICS : Age : Any age Performance status : Karnofsky 70100 % Hematopoietic : Not specify Hepatic : Liver function test great 1.2 time normal Renal : Not specify Other : No major medical psychiatric illness would prevent completion treatment interfere followup No second malignancy within 5 year except superficial nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : At least 90 day since testosterone At least 60 day since finasteride Radiotherapy : No prior radiotherapy Surgery : No 60 day since surgical stag No radical surgery cryosurgery</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>